Welldoc

Welldoc offers a chronic care platform supporting various conditions such as prediabetes, diabetes, hypertension, heart failure, weight management, mental well-being, and sleep apnea. Welldoc's FDA-cleared digital health app, BlueStar, assists individuals in self-managing their diabetes care and strengthens their connections with their healthcare team. The company offers holistic guidance to assist individuals in managing their daily nutrition, physical activity, data tracking, and long-term trends.

In August 2023, the company was the first to receive FDA approval to provide bolus insulin dose recommendations based on continuous glucose monitoring (CGM) readings, and, as of May 2024, the company held 11 FDA clearances and 43 patents for advanced AI and technology and was included in more than 80 clinical publications.

Key customers and partnerships

To expand its solutions, the company has partnered with pharmacy benefit managers, health plans, health systems, and employers, including 1) Dexcom, provider of a CGM system, to offer integrated type 2 diabetes management solutions (in April 2021), 2) LifeScan, a blood glucose monitoring provider, to incorporate Welldoc’s platform into LifeScan’s OneTouch Solutions for diabetes management (in September 2021), and 3) Conifer Health Solutions, a Johnson & Johnson company producing blood glucose meters, to launch a health app called Conifer Connect (in April 2023).

Funding and financials

In March 2016, the company raised USD 29.5 million in a Series B round led by Samsung Ventures, Johnson & Johnson Robotics, and Digital Solutions. The funds were used for commercialization of its BlueStar solution.